Therapeutic Advances in Psychopharmacology
October 8, 2026
Gianluca A. Florineth, Anna L. Boeker, Felix Müller et al.
Background Classic psychedelics show potential for treating psychiatric disorders, yet the psychological framework of psychedelic-assisted therapy (PAT) remains underspecified. As regulatory approval approaches, defining the contribution of psychological interventions to clinical outcomes is critical for both mechanism inference and implementation. Objectives To systematically review the...
Frontiers in Psychiatry
October 8, 2026
Anthony L. Back, Cynthia J. Price, Bonnie A. Mcgregor et al.
Cancer patients arrive for psilocybin therapy with bodies altered by illness and treatment — bodies that they have learned to brace against, dissociate from, or scan for threat. Research on psilocybin-assisted therapy for cancer-related depression and anxiety consistently identifies the quality of the acute subjective experience — reflected in constructs such as acceptance, surrender,...
ePrints Soton
October 7, 2026
Rose Seneviratne
Rates of anxiety, depression, and psychological distress among young adults have increased while mental health services face persistent capacity constraints, strengthening the need for accessible, low-intensity preventive support. Mindfulness-based programmes (MBPs) are widely promoted as one possible response. However, their effects across young adult populations and delivery contexts remain...
BMC Psychiatry
October 7, 2026
Qianqian Wu, Weicheng Li, Zhanjie Luo et al.
Abstract Background Anhedonia, a prominent symptom of major depressive disorder (MDD), severely impairs patients’ quality of life and is challenging to treat. Although esketamine has shown potential in treating anhedonia in adult treatment-resistant MDD, its effects on adolescents remain under-explored. Methods In this study, a prospective, randomized, double-blind, controlled trial was...
BMC Nursing
October 6, 2026
Hui Yan, Yue Zhong, Qiang Ji et al.
To evaluate the effectiveness of mindfulness-based interventions (MBIs), including but not limited to mindfulness-based cognitive therapy (MBCT), mindfulness-based stress reduction (MBSR), and other structured MBIs, in improving cognitive and psychological outcomes in adults with neurological disorders. We searched six databases through April 25, 2025. Eight randomized controlled trials were...
Frontiers in Public Health
October 6, 2026
Vivian W. L. Tsang, Faizan Bhatia, Anne Ferrey et al.
Background: The group therapy model has been recently favored as a means of conducting psychedelic assisted therapies for mental health disorders. However, there is a paucity of literature showing strengths or drawbacks of this approach and comparisons of safety and efficacy to individual therapy. This systematic review aims to address this gap in literature. Methods: We included original...
Progress in neuro-psychopharmacology & biological psychiatry
October 6, 2026
Chad Collyer, Gia Han Le, Maryam Hassan et al.
Short-acting tryptamine psychedelics are emerging as candidate psychiatric therapeutics with pharmacological profiles that may offer practical advantages over longer-acting psychedelics. N,N-dimethyltryptamine (N,N-DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) differ in pharmacokinetic, receptor, and phenomenological properties, while zalsupindole is a putatively non-hallucinogenic...
Bangladesh Journal of Psychiatry
October 5, 2026
Mohammad Shamsul Ahsan, Leuza Mubassara, Ananya Kar et al.
Depressive episodes are common but has great impact either in unipolar or bipolar mood disorder. Medical management of severe depression with suicidal attempts are challenging. The rate of Major Depressive Disorder (MDD) who are non-responders are about 30% of those receiving treatment in research settings. Over the past 15 years, ketamine infusions have demonstrated rapid antidepressant and...
medRxiv
October 5, 2026
Praachi Tiwari, Sandeep M. Nayak, Nathan D. Sepeda et al.
preprint
Importance: Obsessive-Compulsive Disorder (OCD) has a 2% global prevalence, but only about 50% of patients respond to conventional treatment, underscoring the need for additional effective interventions. Objective: To assess the feasibility, safety, and preliminary evidence for efficacy of repeated psilocybin administration in OCD patients who had previously attempted psychotherapy or...
Frontiers in Psychiatry
October 5, 2026
Andreas Paris, Foteini Thoma, Aikaterini Velentza et al.
Recent advances in psychedelic research have renewed interest in the potential therapeutic role of psychedelic-assisted interventions in psychiatry. Early clinical trials suggest that compounds such as psilocybin and MDMA, administered within structured therapeutic frameworks, may produce rapid symptom improvements for conditions including depression, post-traumatic stress disorder, and...